Significant advancements has been seen in recent years within the landscape of central nervous system (CNS), particularly with the emergence of liquid biopsy studies. While the majority of these studies have focused on blood-based biomarkers, there is a growing recognition of the potential of cerebrospinal fluid (CSF) as a source of more specific and sensitive biomarkers. As an ultrafiltrate of blood and in direct contact with the brain and tumor milieu, the CSF offers a wealth of untapped information. However, the exploration of this potential is fraught with challenges and complexities that necessitate careful consideration and further investigation.

The primary aim of this research topic is to bring together leading experts in the field to unravel the mysteries of CSF-based biomarkers for CNS tumors. The goal is to diversify the types of biomarkers under investigation, enrich our understanding of the intricate molecular signatures and pathways associated with CNS tumors, and pave the way for novel diagnostic and therapeutic approaches. Additionally, this research topic seeks to address the challenge of biomarker source localization and gain insights into how researchers are tackling the intricate issue of the blood-brain barrier.

The scope of this research topic is primarily focused on CSF-based biomarker discovery and validation for CNS tumors. We welcome articles addressing, but not limited to, the following themes:

- Studies exploring various domains, including proteomics, metabolomics, genomics, and extracellular vesicles.
- Investigations into the origin and spatial distribution of these biomarkers within the CSF.
- Contributions that explore innovative strategies to overcome the challenges posed by a disrupted blood-brain barrier.
- Studies on both adult and pediatric tumors.
- Research shedding light on the nuances of CSF-based biomarker development, including the safety of CSF acquisition and the clinical implications of utilizing CSF-based biomarkers for CNS tumor management.
- Studies comparing CSF to serum or plasma, with a primary focus on CSF.

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Submit your idea

Impact

Frontiers in Oncology

Participating Journals

Submit your idea

Impact